We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05254210
Recruitment Status : Completed
First Posted : February 24, 2022
Last Update Posted : July 20, 2022
Information provided by (Responsible Party):
Cynosure, Inc.

Brief Summary:
The intended use of the Potenza™ device is to collect clinical data for brow lifting and/or treatment of dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.

Condition or disease Intervention/treatment Phase
Wrinkles Fine Lines Crepey Skin Acne Scars Active Acne Enlarged Pores Loose Skin Device: RF Device (Potenza™) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device
Actual Study Start Date : September 13, 2021
Actual Primary Completion Date : May 17, 2022
Actual Study Completion Date : May 17, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment with RF Device
Subjects may receive up to 3 treatments with the RF device if they are willing to receive treatment for brow lifting and/or present with conditions such as, but not limited to; wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, loose skin on the face, neck and/or body
Device: RF Device (Potenza™)
Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.

Primary Outcome Measures :
  1. Evaluation of baseline photographs compared to post treatment images [ Time Frame: 30 day follow up ]
    Photographs will be evaluated at the baseline and the 30 day follow up. The number of photographs with improvement (based on changes in the skin) from baseline to follow up images will be reported.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A healthy, non-smoking male or female between the age of 18-60 years old.
  • Fitzpatrick skin type I to VI.
  • Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
  • Understands and accepts the obligation and is logistically able to be present for all visits.
  • Is willing to comply with all requirements of the study and sign the informed consent document.

Exclusion Criteria:

  • Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
  • The subject is currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within in the area to be treated 3 months prior to entering this study.
  • The subject has a pacemaker.
  • The subject had previous use of gold thread skin rejuvenation.
  • The subject has a cut, wound, or infected skin on the area to be treated (but skin eruptions may be treated).
  • The subject has a metal implant that interferes with the transmission of energy to the electrical field.
  • The subject has any embedded electronic devices that give or receive a signal.
  • The subject has Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant.
  • The subject is allergic to adhesives such as glues on medical tape: they should be alerted that a rash may occur on the neutral electronic monitoring pad (NEM or neutral pad) site, and an over-the-counter preparation may be used to treat the area.
  • The subject is allergic to gold.
  • The subject has an unrealistic expectation of the results: this is not plastic surgery, and all subjects should be fully informed of the treatment's expected results.
  • The subject has nerve insensitivity to heat in the treatment area or in the neutral pad placement area.
  • The subject has severe laxity or sagging that causes redundant folds of tissue or hanging skin in the area to be treated: this treatment will be ineffective.
  • The subject has used Accutane (isotretinoin) six to twelve months prior to treatment, as this can thin the skin and make it brittle.
  • The subject is taking aspirin or are currently taking antiplatelets, thrombolytics, anti-inflammatories or anticoagulants.
  • The subject has a history of bleeding coagulopathies.
  • The subject is allergic to topical anesthetic.
  • The subject has any of the following conditions:

    • Diabetes
    • Epilepsy
    • Autoimmune disease
    • Herpes simplex
    • HIV
    • Hypertension
    • Dermatitis
  • The subject has keloid formation propensity.
  • Subjects with electronic implants such as cardiac defibrillator. It may interfere with operation of electronic implants or damage the implants, causing risks.
  • The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.

Cautionary Criteria:

  • The subject is prone to fever blisters: they should receive a prophylactic antiviral medication regimen prior to treatment.
  • The subject has lesions in the treatment area that have not been evaluated and diagnosed: they should be evaluated prior to the treatment day.
  • The subject has malignant disease (excluding skin malignancies).
  • The subject has used retinoids in the last seven days in the area to be treated: retinoids can create erythema and cause the skin to become heat sensitive.
  • The subject has used any chemical peels in the last two to three months in the treatment area: subjects should wait until any remaining erythema or side effects have resolved.
  • The subject has tattoos, permanent makeup, and permanent brows in the treatment area: caution must be used. (The ink used in these applications is unregulated and may have metallic components.)
  • The subject has a neuropathic disorder, impaired skin sensation or diabetic neuropathy.
  • The subject has received fillers or neurotoxin injections: subjects should wait two weeks before receiving a Potenza treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05254210

Layout table for location information
United States, California
Profiles Beverly Hills
West Hollywood, California, United States, 90069
Sponsors and Collaborators
Cynosure, Inc.
Layout table for investigator information
Study Director: Jennifer Civiok Director of Clinical Research
Layout table for additonal information
Responsible Party: Cynosure, Inc.
ClinicalTrials.gov Identifier: NCT05254210    
Other Study ID Numbers: CYN20-RF-MN-PROFILES
First Posted: February 24, 2022    Key Record Dates
Last Update Posted: July 20, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Cutis Laxa
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Connective Tissue Diseases